Company intelligence / Profile preview

SINTEF Venture IV

Trondheim, Norway

Ownership: Private
Development stage: Other

Overview

SINTEF Venture IV is a seed-stage venture capital fund managed by SINTEF TTO, the technology transfer office of the SINTEF Group, one of Europe's largest independent research organizations. The fund focuses on commercializing research results and technology developed within SINTEF and the Norwegian University of Science and Technology (NTNU). It invests across several high-tech sectors, with a significant portion of its portfolio dedicated to life sciences, medical technology, and biotechnology. By providing early-stage capital and business development expertise, the fund aims to bridge the gap between laboratory research and commercial market entry for innovative Norwegian startups.

Industry: Investors

Partnerships

Norwegian University of Science and Technology (NTNU)European Investment Fund (EIF)

Beyond the preview

Go deeper on SINTEF Venture IV.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SINTEF Venture IV.

Explore the full profile